TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report published on Tuesday. The firm issued a hold rating on the stock.

TherapeuticsMD Stock Performance

NASDAQ TXMD opened at $1.58 on Tuesday. The firm’s fifty day moving average is $1.69 and its two-hundred day moving average is $1.83. TherapeuticsMD has a one year low of $1.43 and a one year high of $3.07.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share for the quarter. The business had revenue of $0.23 million during the quarter.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently bought a new stake in TherapeuticsMD stock. Prosperity Consulting Group LLC purchased a new position in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 24,500 shares of the company’s stock, valued at approximately $56,000. Prosperity Consulting Group LLC owned approximately 0.21% of TherapeuticsMD as of its most recent SEC filing. 30.74% of the stock is owned by hedge funds and other institutional investors.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.